Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.111909 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xiongyan Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, School of Marine Biology and Fisheries, Key Laboratory of Tropical Biological Resources of Ministry of Education, …. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, COVID-19 Vaccines, SARS-CoV-2, Adjuvants, Immunologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Natural Science Foundation of Hainan Province, National Natural Science Foundation of China, Hainan University.
Abstract (Originalsprache)
Adjuvants enhance the body's immune response to a vaccine, often leading to better protection against diseases. Monophosphoryl lipid A analogues (MPLA, TLR4 agonists), α-galactosylceramide analogues (NKT cell agonists), and imidazoquinoline compounds (TLR7/8 agonists) are emerging novel adjuvants on market or under clinical trials. Despite significant interest in these adjuvants, a direct comparison of their adjuvant activities remains unexplored. We initially assessed the activities of various adjuvants from three distinct categories using the SARS-CoV-2 RBD trimer antigen. TLR4 and TLR7/8 agonists are discovered to elicit robust IgG2a/2b antibodies, which is crucial for eliciting antibody dependent cytotoxicity. While α-galactosylceramide analogs induced mainly IgG1 antibody. Then, because of the flexibility of the TLR7/8 agonist, we designed and synthesized a tri-component self-adjuvanting SARS-CoV-2 RBD vaccine, featuring a covalent TLR7 agonist and targeting mannoside. Animal studies indicated that this vaccine generated antigen-specific humoral immunity. Yet, its immunogenicity seems compromised, indicating the complexity of the vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, School of Marine Biology and Fisheries, Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China.
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China.
- School of Pharmaceutical Sciences, School of Marine Biology and Fisheries, Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China. Electronic address: chengli.z…
Förderung
- Natural Science Foundation of Hainan Province
- National Natural Science Foundation of China
- Hainan University
Zitieren
APA
Meng, X., Xu, Y., Yang, J., Meng, S., Ding, N., Sun, T., & Zong, C. (2024). Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.111909
Vancouver
Meng X, Xu Y, Yang J, Meng S, Ding N, Sun T, et al. Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.111909
BibTeX
@article{Meng2024,
author = {Meng, Xiongyan and Xu, Ying and Yang, Jing and Meng, Shuai and Ding, Ning and Sun, Tiantian and Zong, Chengli},
title = {Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.111909}
}
EUVIMED